MedTrace Logo

Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics

NCT03092037 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2022-08-16

No results posted yet for this study

Summary

The proposed study will investigate the relationship between genetic variants and serum contraceptive hormone levels, specifically the progestin etonogestrel. This study will provide the foundation for future pharmacogenomic investigations of more commonly used contraceptive methods with higher failure rates.

Conditions

  • Contraception

Interventions

PROCEDURE

Blood draw

The Investigators will collect serum and whole blood from participants.

Sponsors & Collaborators

Principal Investigators

  • Aaron Lazorwitz, MD · University of Colorado, Denver

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-23
Primary Completion
2022-04-29
Completion
2022-04-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092037 on ClinicalTrials.gov